ATHA Live signals | Maximize Profits with Getagraph.com

SELL 101324 min ago

@ $3.22

Issued: 14 Feb 2024 @ 09:30

Return: -37.58%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 1.26 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 16:00):

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation...

Stats
Today's Volume	77 927.00
Average Volume	355 859
Market Cap	77.04M
EPS	$0 ( 2024-03-28 )
Next earnings date	( $-0.800 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.650
ATR14	$0.00500 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	San Martin Javier	Buy	400 000	Stock Option (Right to Buy)
2024-04-15	San Martin Javier	Buy	0
2024-02-15	Litton Mark James	Buy	650 000	Stock Option (Right to Buy)
2024-02-14	Worthington Mark	Buy	220 000	Stock Option (Right to Buy)
2024-02-14	Church Kevin	Buy	220 000	Stock Option (Right to Buy)

INSIDER POWER
98.59
Last 99 transactions
Buy: 6 665 546 \| Sell: 65 252

Volume Correlation

Long: -0.30 (neutral)

Short: -0.52 (weak negative)

Signal:(20.86) Neutral

Athira Pharma, Inc. Correlation

10 Most Positive Correlations
SGBX	0.898
VNET	0.893
SRTS	0.888
ABST	0.885
CNDT	0.883
RYTM	0.883
FREQ	0.882
INFI	0.876
FNWB	0.875
SBBP	0.874

10 Most Negative Correlations
RDUS	-0.883
CRWD	-0.879
LVO	-0.878
TYHT	-0.877
PAE	-0.873
ZGNX	-0.873
ICON	-0.873
PETV	-0.869
MRNS	-0.859
RDI	-0.851

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Athira Pharma, Inc. Correlation - Currency/Commodity

-0.46
( neutral )

-0.52
( weak negative )

0.00
( neutral )

-0.51
( weak negative )

-0.11
( neutral )

Athira Pharma, Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-969 000 (0.00 %)
EPS:	$-3.09

Q4	2023
Revenue:	$0
Gross Profit:	$-245 000 (0.00 %)
EPS:	$-0.720

Q3	2023
Revenue:	$0
Gross Profit:	$-244 000 (0.00 %)
EPS:	$-0.870

Q2	2023
Revenue:	$0
Gross Profit:	$-297 000 (0.00 %)
EPS:	$-0.780

Financial Reports:

No articles found.

Athira Pharma, Inc.

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.